Table 1 Clinical information
From: Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI
| Â | #1 | #2 | #3 | #4 | #5 | #6 |
|---|---|---|---|---|---|---|
Age (years) | 52 | 18 | 65 | 26 | 48 | 18 |
Sex | M | F | M | M | F | F |
Tumor stage (initial) | pT2 pN0 cM0 (UICC II) | cT1 cN1 cM1 (UICC IVB) | cT1 cN0 cM0 (UICC I) | pT2 cN0 cM0 (UICC II) | cT3b cN0 cM0 (UICC IIIB) | pT3b pN1 cM0 (UICC IVA) |
Time to diagnosis (months) | 1 | 10 | 1 | 1 | 1 | 20 |
TACE prior to gadoxetic acid enhanced MRI | No | Yes | Yes | No | Yes | No |
Treatment | Resection | Sorafenib | TACE, Sorafenib | Resection | Sorafenib | Resection |
Survival times | PFS ongoing for 24Â months | OS 2Â months | OS 29Â months | PFS ongoing for 46Â months | Lost to follow-up | OS 7Â months |